Osteopore continues its expansion in Europe after making a first sale in Spain

Osteopore’s shipment to Spain follows its agreement in Colombia earlier this week.

Specialist in bone healing, Osteopore (ASX:OSX), expanded its presence in Europe with a first delivery of its regenerative cranial (skull) implants in Spain.

Initial orders have been received from Osteopore’s distribution partner based in Spain, Acuna and Fombona, one of the main distributors of medical and surgical equipment in the region.

This development follows recent expansion in Latin America, where the first orders were shipped to Colombia earlier this week.

Although the initial Spanish sales will not be significant in terms of revenue, Osteopore believes they represent an excellent opportunity to enter new markets and drive adoption by surgeons worldwide.

It will also help to introduce and initiate the clinical use of Osteopore’s cranial implants in the Spanish market.

“Achieving the first sales in Spain is another fantastic milestone for the business and shows our team’s ability to execute on our strategy to enter new markets,” said Osteopore CEO Mark Leong.

Leong added that Osteopore is making rapid progress to regain momentum after Covid, supported by a fully dedicated sales team ready to take advantage of a large backlog of elective surgeries that have been postponed during the pandemic.

The opportunity in Spain

The potential market for Osteopore implants in Spain is estimated at approximately 40,000 cases per year.

The partnership with Acuña y Fombona, which has over 50 years of experience in the industry, is expected to capture some of this market by leveraging Acuña’s extensive networks in various key cities in the region.

These cities include Madrid, Barcelona, ​​Valencia, Seville and Salamanca, and Acuña’s headquarters in Gijón.

The initial shipment will also provide Acuña y Fombona with sufficient inventory to engage its established network of medical professionals, hospitals and health services.

Acuña y Fombona’s Managing Director, Sergio López-Fombona, said of the agreement, “It will allow us to expand our product portfolio with exceptional technology and meet a wider range of needs across our network of surgeons and ultimately to give a better treatment opportunity to their patients.

Tailwinds after the pandemic

Osteopore claims that its craniofacial implants are premium ready-to-use products that can be manufactured on a large scale.

This flexibility allows the implants to potentially be used in more than 1.1 million craniofacial procedures performed worldwide.

The unique property of Osteopore implants is that they can dissolve over time to leave only healthy, natural bone. Osteopore also stated that its implants have far exceeded traditional implant methods in terms of design, post-operative complications, as well as associated long-term patient costs.

As the effects of COVID-19 begin to diminish across the world, Osteopore is beginning to experience increased engagement with hospitals, surgeons, and healthcare decision makers.

These favorable winds open up opportunities for market penetration and allow the company to pursue its vision of becoming the world reference in bone and tissue regeneration.

With regulatory clearances and distribution partners secured in many major markets, Osteopore is rapidly moving towards growing its footprint in more regions where immediate opportunities exist.

To conquer these markets, a complementary pipeline of new products is currently being developed for other bone regeneration applications.

This article was developed in conjunction with Osteopore, a Stockhead advertiser at the time of publication.

This article does not constitute advice on financial products. You should consider obtaining independent advice before making any financial decisions.

You may be interested in

Comments are closed.